Baillie Gifford & Co. raised its stake in shares of Celgene Co. (NASDAQ:CELG) by 1.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 671,088 shares of the biopharmaceutical company’s stock after buying an additional 12,144 shares during the period. Baillie Gifford & Co.’s holdings in Celgene were worth $77,679,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CELG. First Financial Corp IN boosted its position in Celgene by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 228 shares during the period. Barnett & Company Inc. boosted its position in Celgene by 18.3% in the third quarter. Barnett & Company Inc. now owns 1,130 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 175 shares during the period. Jolley Asset Management LLC boosted its position in Celgene by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares during the period. Smithfield Trust Co. boosted its position in Celgene by 2.2% in the third quarter. Smithfield Trust Co. now owns 1,310 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 28 shares during the period. Finally, Integrated Investment Consultants LLC boosted its position in Celgene by 2.2% in the third quarter. Integrated Investment Consultants LLC now owns 1,369 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 30 shares during the period. 77.68% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Shares of Celgene Co. (NASDAQ:CELG) opened at 126.51 on Tuesday. The stock has a market cap of $98.42 billion, a PE ratio of 50.81 and a beta of 1.74. Celgene Co. has a 52-week low of $94.42 and a 52-week high of $127.64. The company’s 50-day moving average price is $120.08 and its 200-day moving average price is $113.41.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, January 26th. The biopharmaceutical company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.59 by $0.02. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $3.03 billion. Celgene had a return on equity of 77.95% and a net margin of 17.80%. Celgene’s quarterly revenue was up 16.3% on a year-over-year basis. During the same period last year, the business posted $1.18 EPS. On average, equities research analysts forecast that Celgene Co. will post $7.22 earnings per share for the current fiscal year.

Your IP Address:

Several equities analysts have recently issued reports on CELG shares. Cann reissued a “buy” rating and set a $141.00 target price on shares of Celgene in a research note on Tuesday, December 6th. Cantor Fitzgerald set a $159.00 target price on Celgene and gave the company a “buy” rating in a research note on Monday, December 5th. Credit Suisse Group AG set a $145.00 price target on Celgene and gave the company a “buy” rating in a research report on Wednesday, November 30th. Jefferies Group LLC set a $140.00 price target on Celgene and gave the company a “buy” rating in a research report on Wednesday, November 30th. Finally, Vetr upgraded Celgene from a “hold” rating to a “buy” rating and set a $128.85 price target on the stock in a research report on Tuesday, November 29th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have issued a buy rating to the company. Celgene has a consensus rating of “Buy” and an average price target of $139.50.

In other Celgene news, insider Rupert Vessey sold 4,000 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $124.42, for a total transaction of $497,680.00. Following the transaction, the insider now directly owns 778 shares in the company, valued at approximately $96,798.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.97% of the company’s stock.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.